GoodCap
GoodCap Pharmaceuticals is a Canadian company dedicated to developing psilocybin-based therapeutics and natural therapies targeting neuroinflammation to treat psychiatric and neurodegenerative disorders. Founded in 2018, the company focuses on understanding and disrupting inflammation and disease processes at their core, aiming to improve mental health and brain health for millions affected by conditions such as PTSD, depression, Parkinson's, and Alzheimer's. It also engages in retail through its brand 'A Good Mushroom,' selling functional mushroom products. The company's mission is to help those who desperately need better mental healthcare, with a focus on PTSD, which is growing rapidly in the post-COVID world. GoodCap aims to provide more effective and accessible medicines, addressing the overlooked complexity of patient experiences and offering broader, safer impact.
Industries
Nr. of Employees
small (1-50)
Products
Multi‑component anti‑inflammatory oral therapeutic candidate
A combination oral formulation pairing receptor‑targeted agonists with transient receptor potential channel ligands and natural anti‑inflammatory molecules intended to modulate pro‑inflammatory cytokines and oxidative stress implicated in neuroinflammatory psychiatric conditions.
GCAP001
An oral, at-home therapeutic platform designed to interrupt chronic neuroinflammation and impaired neural repair at two points simultaneously for psychiatric and neurodegenerative disorders.
Multi‑component anti‑inflammatory oral therapeutic candidate
A combination oral formulation pairing receptor‑targeted agonists with transient receptor potential channel ligands and natural anti‑inflammatory molecules intended to modulate pro‑inflammatory cytokines and oxidative stress implicated in neuroinflammatory psychiatric conditions.
GCAP001
An oral, at-home therapeutic platform designed to interrupt chronic neuroinflammation and impaired neural repair at two points simultaneously for psychiatric and neurodegenerative disorders.
Services
Partnered preclinical studies with academic groups to characterize metabolism, evaluate low‑dose formulations, and assess anti‑inflammatory and behavioral outcomes.
Development of multi‑component formulations combined with CMC and supply‑chain planning and support for composition‑of‑matter patent filings.
Advisory services covering regulatory interactions, commercialization planning, and capital‑raising strategies for CNS and psychiatric drug programs.
Support for preparing preclinical data and manuscripts for peer‑reviewed publication to strengthen translational evidence and regulatory packages.
Partnered preclinical studies with academic groups to characterize metabolism, evaluate low‑dose formulations, and assess anti‑inflammatory and behavioral outcomes.
Development of multi‑component formulations combined with CMC and supply‑chain planning and support for composition‑of‑matter patent filings.
Advisory services covering regulatory interactions, commercialization planning, and capital‑raising strategies for CNS and psychiatric drug programs.
Support for preparing preclinical data and manuscripts for peer‑reviewed publication to strengthen translational evidence and regulatory packages.
Expertise Areas
- Neuroinflammation therapeutics
- Psychedelic‑assisted and receptor‑targeted therapeutics
- Preclinical pharmacology and animal models
- Inflammation biomarker profiling and cytokine assessment
Key Technologies
- Rodent disease models (DSS colitis, LPS challenge)
- In vitro macrophage assays (THP‑1 and similar)
- Human 3D intestinal tissue models
- Cytokine immunoassays (ELISA and related platforms)
News & Updates
GoodCap Wellness Inc. announced the appointment of a new Board of Directors including industry experts in pharmaceutical drug development, biotechnology, brand creation, and business development. Rochelle Stenzler was appointed as Chair. The company was formerly named Cannaglobal Canada Co. Inc.
Sansero Life Sciences partnered with the University of Toronto to conduct a preclinical study on low-dose psilocybin, aiming to understand its metabolism and effects on mental health conditions.
The merger of CannaGlobal Canada Co. Inc., Sansero Life Sciences Inc., and Rise Wellness resulted in the formation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and natural compounds for wellness.
The creation of CannaGlobal Wellness was announced, focusing on developing and commercializing psilocybin-based neurotherapeutics and wellness solutions.
GoodCap Wellness Inc. announced the appointment of a new Board of Directors including industry experts in pharmaceutical drug development, biotechnology, brand creation, and business development. Rochelle Stenzler was appointed as Chair. The company was formerly named Cannaglobal Canada Co. Inc.
Sansero Life Sciences partnered with the University of Toronto to conduct a preclinical study on low-dose psilocybin, aiming to understand its metabolism and effects on mental health conditions.
The merger of CannaGlobal Canada Co. Inc., Sansero Life Sciences Inc., and Rise Wellness resulted in the formation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and natural compounds for wellness.
The creation of CannaGlobal Wellness was announced, focusing on developing and commercializing psilocybin-based neurotherapeutics and wellness solutions.